Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial

Peter L. Havens, Charles B. Stephensen, Rohan Hazra, Patricia M. Flynn, Craig M. Wilson, Brandy Rutledge, James Bethel, Cynthia G. Pan, Leslie R. Woodhouse, Marta D. Van Loan, Nancy Liu, Jorge Lujan-Zilbermann, Alyne Baker, Bill G. Kapogiannis, Kathleen Mulligan

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background. The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX) in youth infected with human immunodeficiency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF). Methods. This randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 years based on stable treatment with cART containing TDF (n = 118) or no TDF (noTDF; n = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), administered at 0, 4, and 8 weeks. Outcomes included change in TRP, PTH, BAP, and CTX from baseline to week 12 by TDF/noTDF; and VITD/placebo.Results.At baseline, VITD and placebo groups were similar except those on TDF had lower TRP and higher PTH and CTX. At week 12, 95% in the VITD group had sufficient serum 25-hydroxy vitamin D (25-OHD; ≥20 ng/mL), increased from 48% at baseline, without change in placebo (P <. 001). PTH decreased in the TDF group receiving VITD (P =. 031) but not in the noTDF group receiving VITD, or either placebo group. The decrease in PTH with VITD in those on TDF occurred with insufficient and sufficient baseline 25-OHD (mean PTH change,-7.9 and-6.2 pg/mL; P =. 031 and. 053, respectively). Conclusions. In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of baseline 25-OHD concentration. Clinical Trials Registration. NCT00490412.

Original languageEnglish (US)
Pages (from-to)1013-1025
Number of pages13
JournalClinical Infectious Diseases
Volume54
Issue number7
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Tenofovir
Cholecalciferol
Parathyroid Hormone
Vitamin D
Randomized Controlled Trials
Placebos
HIV
Phosphates
Alkaline Phosphatase
Bone and Bones

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Havens, P. L., Stephensen, C. B., Hazra, R., Flynn, P. M., Wilson, C. M., Rutledge, B., ... Mulligan, K. (2012). Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial. Clinical Infectious Diseases, 54(7), 1013-1025. https://doi.org/10.1093/cid/cir968

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir : A randomized, placebo-controlled trial. / Havens, Peter L.; Stephensen, Charles B.; Hazra, Rohan; Flynn, Patricia M.; Wilson, Craig M.; Rutledge, Brandy; Bethel, James; Pan, Cynthia G.; Woodhouse, Leslie R.; Van Loan, Marta D.; Liu, Nancy; Lujan-Zilbermann, Jorge; Baker, Alyne; Kapogiannis, Bill G.; Mulligan, Kathleen.

In: Clinical Infectious Diseases, Vol. 54, No. 7, 01.04.2012, p. 1013-1025.

Research output: Contribution to journalArticle

Havens, PL, Stephensen, CB, Hazra, R, Flynn, PM, Wilson, CM, Rutledge, B, Bethel, J, Pan, CG, Woodhouse, LR, Van Loan, MD, Liu, N, Lujan-Zilbermann, J, Baker, A, Kapogiannis, BG & Mulligan, K 2012, 'Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial', Clinical Infectious Diseases, vol. 54, no. 7, pp. 1013-1025. https://doi.org/10.1093/cid/cir968
Havens, Peter L. ; Stephensen, Charles B. ; Hazra, Rohan ; Flynn, Patricia M. ; Wilson, Craig M. ; Rutledge, Brandy ; Bethel, James ; Pan, Cynthia G. ; Woodhouse, Leslie R. ; Van Loan, Marta D. ; Liu, Nancy ; Lujan-Zilbermann, Jorge ; Baker, Alyne ; Kapogiannis, Bill G. ; Mulligan, Kathleen. / Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir : A randomized, placebo-controlled trial. In: Clinical Infectious Diseases. 2012 ; Vol. 54, No. 7. pp. 1013-1025.
@article{ad3a970d89994b05aa3b04e4d7e4d73d,
title = "Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial",
abstract = "Background. The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX) in youth infected with human immunodeficiency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF). Methods. This randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 years based on stable treatment with cART containing TDF (n = 118) or no TDF (noTDF; n = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), administered at 0, 4, and 8 weeks. Outcomes included change in TRP, PTH, BAP, and CTX from baseline to week 12 by TDF/noTDF; and VITD/placebo.Results.At baseline, VITD and placebo groups were similar except those on TDF had lower TRP and higher PTH and CTX. At week 12, 95{\%} in the VITD group had sufficient serum 25-hydroxy vitamin D (25-OHD; ≥20 ng/mL), increased from 48{\%} at baseline, without change in placebo (P <. 001). PTH decreased in the TDF group receiving VITD (P =. 031) but not in the noTDF group receiving VITD, or either placebo group. The decrease in PTH with VITD in those on TDF occurred with insufficient and sufficient baseline 25-OHD (mean PTH change,-7.9 and-6.2 pg/mL; P =. 031 and. 053, respectively). Conclusions. In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of baseline 25-OHD concentration. Clinical Trials Registration. NCT00490412.",
author = "Havens, {Peter L.} and Stephensen, {Charles B.} and Rohan Hazra and Flynn, {Patricia M.} and Wilson, {Craig M.} and Brandy Rutledge and James Bethel and Pan, {Cynthia G.} and Woodhouse, {Leslie R.} and {Van Loan}, {Marta D.} and Nancy Liu and Jorge Lujan-Zilbermann and Alyne Baker and Kapogiannis, {Bill G.} and Kathleen Mulligan",
year = "2012",
month = "4",
day = "1",
doi = "10.1093/cid/cir968",
language = "English (US)",
volume = "54",
pages = "1013--1025",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir

T2 - A randomized, placebo-controlled trial

AU - Havens, Peter L.

AU - Stephensen, Charles B.

AU - Hazra, Rohan

AU - Flynn, Patricia M.

AU - Wilson, Craig M.

AU - Rutledge, Brandy

AU - Bethel, James

AU - Pan, Cynthia G.

AU - Woodhouse, Leslie R.

AU - Van Loan, Marta D.

AU - Liu, Nancy

AU - Lujan-Zilbermann, Jorge

AU - Baker, Alyne

AU - Kapogiannis, Bill G.

AU - Mulligan, Kathleen

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background. The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX) in youth infected with human immunodeficiency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF). Methods. This randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 years based on stable treatment with cART containing TDF (n = 118) or no TDF (noTDF; n = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), administered at 0, 4, and 8 weeks. Outcomes included change in TRP, PTH, BAP, and CTX from baseline to week 12 by TDF/noTDF; and VITD/placebo.Results.At baseline, VITD and placebo groups were similar except those on TDF had lower TRP and higher PTH and CTX. At week 12, 95% in the VITD group had sufficient serum 25-hydroxy vitamin D (25-OHD; ≥20 ng/mL), increased from 48% at baseline, without change in placebo (P <. 001). PTH decreased in the TDF group receiving VITD (P =. 031) but not in the noTDF group receiving VITD, or either placebo group. The decrease in PTH with VITD in those on TDF occurred with insufficient and sufficient baseline 25-OHD (mean PTH change,-7.9 and-6.2 pg/mL; P =. 031 and. 053, respectively). Conclusions. In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of baseline 25-OHD concentration. Clinical Trials Registration. NCT00490412.

AB - Background. The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX) in youth infected with human immunodeficiency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF). Methods. This randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 years based on stable treatment with cART containing TDF (n = 118) or no TDF (noTDF; n = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), administered at 0, 4, and 8 weeks. Outcomes included change in TRP, PTH, BAP, and CTX from baseline to week 12 by TDF/noTDF; and VITD/placebo.Results.At baseline, VITD and placebo groups were similar except those on TDF had lower TRP and higher PTH and CTX. At week 12, 95% in the VITD group had sufficient serum 25-hydroxy vitamin D (25-OHD; ≥20 ng/mL), increased from 48% at baseline, without change in placebo (P <. 001). PTH decreased in the TDF group receiving VITD (P =. 031) but not in the noTDF group receiving VITD, or either placebo group. The decrease in PTH with VITD in those on TDF occurred with insufficient and sufficient baseline 25-OHD (mean PTH change,-7.9 and-6.2 pg/mL; P =. 031 and. 053, respectively). Conclusions. In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of baseline 25-OHD concentration. Clinical Trials Registration. NCT00490412.

UR - http://www.scopus.com/inward/record.url?scp=84858137629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858137629&partnerID=8YFLogxK

U2 - 10.1093/cid/cir968

DO - 10.1093/cid/cir968

M3 - Article

C2 - 22267714

AN - SCOPUS:84858137629

VL - 54

SP - 1013

EP - 1025

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -